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Phosphoproteome analysis of isoflurane-protected heart
mitochondria: phosphorylation of adenine nucleotide
translocator-1 on Tyr194 regulates mitochondrial function
Abstract
AIMS: Reversible phosphorylation of mitochondrial proteins is essential in the regulation of respiratory
function, energy metabolism, and mitochondrion-mediated cell death. We hypothesized that
mitochondrial protein phosphorylation plays a critical role in cardioprotection during pre and
postconditioning, two of the most efficient anti-ischaemic therapies. METHODS AND RESULTS:
Using phosphoproteomic approaches, we investigated the profiles of phosphorylated proteins in Wistar
rat heart mitochondria protected by pharmacological pre and postconditioning elicited by isoflurane.
Sixty-one spots were detected by two-dimensional blue-native gel electrophoresis-coupled Western
blotting using a phospho-Ser/Thr/Tyr-specific antibody, and 45 of these spots were identified by
matrix-assisted laser desorption/ionization-time of flight mass spectrometry. Eleven protein spots related
to oxidative phosphorylation, energy metabolism, chaperone, and carrier functions exhibited significant
changes in their phosphorylation state when protected mitochondria were compared with unprotected.
Using a phosphopeptide enrichment protocol followed by liquid chromatography-MS/MS, 26 potential
phosphorylation sites were identified in 19 proteins. Among these, a novel phosphorylation site was
detected in adenine nucleotide translocator-1 (ANT1) at residue Tyr(194). Changes in ANT
phosphorylation between protected and unprotected mitochondria were confirmed by
immunoprecipitation. The biological significance of ANT phosphorylation at Tyr(194) was further
tested with site-directed mutagenesis in yeast. Substitution of Tyr(194) with Phe, mimicking the
non-phosphorylated state, resulted in the inhibition of yeast growth on non-fermentable carbon sources,
implying a critical role of phosphorylation at this residue in regulating ANT function and cellular
respiration. CONCLUSIONS: Our analysis emphasizes the regulatory functions of the
phosphoproteome in heart mitochondria and reveals a novel, potential link between bioenergetics and
cardioprotection.
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Aims Reversible phosphorylation of mitochondrial proteins is essential in the regulation of respiratory
function, energy metabolism, and mitochondrion-mediated cell death. We hypothesized that mitochon-
drial protein phosphorylation plays a critical role in cardioprotection during pre and postconditioning,
two of the most efﬁcient anti-ischaemic therapies.
Methods and results Using phosphoproteomic approaches, we investigated the proﬁles of phosphory-
lated proteins in Wistar rat heart mitochondria protected by pharmacological pre and postconditioning
elicited by isoﬂurane. Sixty-one spots were detected by two-dimensional blue-native gel electrophoresis-
coupled Western blotting using a phospho-Ser/Thr/Tyr-speciﬁc antibody, and 45 of these spots were ident-
iﬁed by matrix-assisted laser desorption/ionization-time of ﬂight mass spectrometry. Eleven protein spots
related to oxidative phosphorylation, energy metabolism, chaperone, and carrier functions exhibited
signiﬁcant changes in their phosphorylation state when protected mitochondria were compared with
unprotected. Using a phosphopeptide enrichment protocol followed by liquid chromatography-MS/MS,
26 potential phosphorylation sites were identiﬁed in 19 proteins. Among these, a novel phosphorylation
site was detected in adenine nucleotide translocator-1 (ANT1) at residue Tyr194. Changes in ANT phos-
phorylation between protected and unprotected mitochondria were conﬁrmed by immunoprecipitation.
The biological signiﬁcance of ANT phosphorylation at Tyr194 was further tested with site-directed muta-
genesis in yeast. Substitution of Tyr194 with Phe, mimicking the non-phosphorylated state, resulted in
the inhibition of yeast growth on non-fermentable carbon sources, implying a critical role of phosphoryl-
ation at this residue in regulating ANT function and cellular respiration.
Conclusions Our analysis emphasizes the regulatory functions of the phosphoproteome in heart mito-
chondria and reveals a novel, potential link between bioenergetics and cardioprotection.
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1. Introduction
Pre and postconditioning are two of the most effective
measures against myocardial infarction, reducing infarct
size by up to 70%. Ischaemic preconditioning, ﬁrst described
in 1986,1 is a biological process, whereby a transient stressful
stimulus induces a protective state against a more prolonged,
potentially lethal insult. It can be induced by brief ischaemic
episodes or by pharmacological means.2 In contrast, postcon-
ditioning, ﬁrst reported in 2003,3 is a process whereby ischae-
mic heart damage is markedly reduced through brief cycles of
alternating ischaemia and reperfusion or administration of
speciﬁc drugs right at the onset of reperfusion. Despite
having location at the opposite sites of ischaemia, pre and
postconditioning share numerous signalling pathways,4
including the so-called reperfusion injury salvage kinases
(‘RISK’), protein kinase B/Akt and p42/44 extracellular
signal-regulated kinase 1/2, which converge at themitochon-
drial level preventing permeability transition through
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phosphorylation and inhibition of glycogen synthase
kinase-3b,5 by an yet unknown mechanism.
Mitochondria plays a central role in ischaemia-reperfusion
damage of the heart6–8 and hence, are promising targets
for novel anti-ischaemic therapies. These complex double
membrane-enclosed organelles are not only responsible for
ATP production but are also involved in the regulation of cell
metabolism, differentiation, Ca2þ homeostasis, and death
signalling. To meet the dynamic cellular requirements, mito-
chondrial function must be tightly and rapidly regulated. An
increasing body of evidence points to protein phosphorylation
as the key regulatory mechanism responsible for mitochon-
drial regulation.9 Indeed, various kinases, namely protein
kinase A, B, C, and G, mitogen-activated protein kinases, gly-
cogen synthase kinase-3b, hexokinase, creatine kinase 2, Src
kinase family members were identiﬁed in or in close associ-
ation with mitochondria.9–13 Although recent studies shed
new light on the role of phosphorylation as an important post-
translational modiﬁcation in respiratory chain proteins of
heart mitochondria,14–17 only a limited number of phospho-
proteins have been characterized so far.
The aim of this study was to determine the phosphoprotein
proﬁles of pre andpostconditioned, i.e. protectedheartmito-
chondria using proteomics analysis and to compare these with
the proﬁle of unprotected mitochondria exposed to
ischaemia-reperfusion alone. This could ultimately unravel
novel phosphorylation sites potentially involved in cardiopro-
tection. Using site-directed mutagenesis in the yeast, an
established model of mitochondrial function, the biological
signiﬁcance of one of the newly detected phosphorylation
sites, namely Tyr194 of the adenine nucleotide translocator-1
(ANT1), could be conﬁrmed. Our study adds a new aspect to
the mechanisms underlying cardioprotection and points to
the importance of mitochondria in this context.
2. Methods
An expanded Methods section is available in the online data
supplement.
2.1. Experimental protocols
Hearts from Wistar rats were perfused in a non-circulating Langen-
dorff apparatus with Krebs-Henseleit buffer gassed with 95% O2 and
5% CO2 at pH 7.4 and 378C, and subsequently exposed to 40 min of
global no-ﬂow ischaemia followed by 15 min of reperfusion
(Figure 1). Four hearts were assigned to each of the following four
groups (Figure 1): (1) CTRL (control group), time-matched perfusion
without ischaemia; (2) ISCH, test ischaemia followed by 15 min
reperfusion; (3) PreC (pharmacological preconditioning) induced
by isoﬂurane18 administered for 15 min at 1.5 minimum alveolar
concentration (1.5 MAC, corresponding to 2.1 vol%) and washed
out for 10 min prior to test ischaemia; (4) PostC (pharmacological
postconditioning) induced by 15 min isoﬂurane administration at
1.5 MAC right at the onset of reperfusion after test ischaemia.
The buffer solution was equilibrated with isoﬂurane using an
Isotec 3 vaporizer (Datex-Ohmeda, Tewksbury, MA, USA) with an
air bubbler. Isoﬂurane concentrations were also measured in the
buffer solution using a gas chromatograph (Perkin-Elmer, Norwalk,
CT, USA): 0.54+0.06 mM. Left ventricular developed pressure and
coronary ﬂow were recorded as previously described.19
2.2. Isolation of mitochondria from rat heart tissue
Mitochondrial fractions were isolated as previously described.20,21
Brieﬂy, hearts were minced and homogenized in ice-cold homogen-
ization buffer. After centrifugation, crude mitochondria were pel-
leted from the post-nuclear supernatant by centrifugation. The
resultant supernatants were used as cytoplasmic fraction. Enriched
mitochondria were resuspended in buffer, and puriﬁed in a 25%
Percoll density gradient. After washing, mitochondrial proteins
were solubilized and purity of the mitochondrial preparations was
assessed by Western blotting using speciﬁc markers. The following
antibodies were used: goat polyclonal anti-ANT antibody (N-19,
Santa Cruz Biotechnology, USA), goat polyclonal anti-VDAC1 anti-
body (N-18, Santa Cruz Biotechnology), mouse monoclonal anti-
NDUFS4 (MS104, MitoSciences, Eugene, OR, USA), rabbit polyclonal
anti-sMtCK (a kind gift from Dr Theo Wallimann),22 monoclonal
mouse anti-calreticulin (BD Transduction Laboratories, Allschwil,
Switzerland), polyclonal rabbit anti-catalase (Calbiochem, UK),
and monoclonal anti-alpha tubulin (Sigma, St Louis, MO, USA).
2.3. Gel-based proteomics approach
Two-dimensional blue-native/sodium dodecyl sulphate gel electro-
phoresis (2D-BN-PAGE) was carried out as described by Scha¨gger.23
Western blotting was performed using monoclonal anti-phospho-
Ser/Thr/Tyr antibody (SMP101, Assay Designs, LuBioScience,
Switzerland).24 Identiﬁcation of gel spots was accomplished by
matrix-assisted laser desorption/ionization-time of ﬂight mass spec-
trometry (MALDI-TOF-MS).
2.4. Gel-free proteomics approach
After in-solution digestion, the peptide-containing solution was
subjected to strong cation exchange chromatography and immobilized
metal ion afﬁnity chromatography for selective phosphopeptide
enrichment. Phosphopeptides were identiﬁed by liquid chromato-
graphy-electrospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS) using linear ion trap-Fourier transform-ion cyclotron resonance
and nanoﬂow reverse-phase high performance liquid chromatography
separation followed by MALDI-TOF-MS/MS analysis.25
2.5. Immunoprecipitation
ANT protein was immunoprecipitated from puriﬁed rat heart mito-
chondrial fractions using goat polyclonal anti-ANT antibody (N-19,
Santa Cruz Biotechnology, USA) coupled to protein G-sepharose
(Amersham Biosciences).
2.6. Preparation of plasmids and yeast culture
conditions
The AseI and BamHI fragment of human ANT1 cDNA was ampliﬁed by
polymerase chain reaction using pcDNA3-myc-ANT1 as a template,
which was subcloned into NdeI and BamHI sites of pRS314-YA2P
vector to generate pRS314-hANT1. The hANT1Y194F mutant was
Figure 1 Scheme of treatment protocols. PreC: preconditioning with isoﬂur-
ane (2.1 vol% for 15 min followed by 10 min of washout) prior to 40 min of test
ischaemia. PostC: postconditioning with isoﬂurane (2.1 vol% during the ﬁrst
15 min of reperfusion) after 40 min of test ischaemia. ISCH: non-
preconditioned hearts exposed to 40 min of ischaemia. CTRL: time-matched
perfusion. In each group, four hearts were used for analysis.
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generated using the QuickChange kit (Stratagene Europe, The Nether-
lands) and the mutagenic primers: 50-CTACTTCGGAGTCTTTGATACTGC
CAAGG-30, and 50-CCTTGGCAGTATCAAAGACTCCGAAGTAG-30. The
pRS314-YA2P vectors encoding hANT1 and hANT1Y194F were
transformed into the triple AAC-disrupted Saccharomyces cerevisiae
JL-1-3 strain (MATa ade2-1 trp1-1 ura3-1 can1-100 aac1::LEU2
aac2::HIS3 aac3::URA) by the lithium chloride method. Yeast strains
were grown on plates containing fermentable (glucose) and non-
fermentable (glycerol, lactate) carbon sources.
2.7. Statistics
For analysis of protein changes, unpaired t-tests of normalized spot
intensities between groups were used. For analysis of haemo-
dynamic data, unpaired t-test was used to compare groups at iden-
tical time points, and paired t-test to compare within groups over
time (SigmaStat v 2.0; SPSS Science, Chicago, IL, USA). P-values,
0.05 were considered signiﬁcant.
3. Results
3.1. Effective myocardial protection and purity
of mitochondrial fractions from rat hearts
Protection by isoﬂurane pre and postconditioning was con-
ﬁrmed by functional recovery and coronary ﬂow measure-
ments (see Supplementary material online, Table S1). The
purity of mitochondrial fractions was carefully checked by
Western blot analysis. Figure 2 shows no contamination of
the mitochondrial fraction (adenine nucleotide translocator,
voltage-dependent anion channel 1, NADH dehydrogenase
(ubiquinone) Fe-S protein 4, and sarcomeric mitochondrial
creatine kinase) with cytosol (a-tubulin), endoplasmic reti-
culum (calreticulin), or peroxisome (catalase).
3.2. Differences in protein phosphorylation
between protected (pre and postconditioned)
vs. unprotected heart mitochondria
The BN-PAGE technique allows separation of hydrophobic
protein complexes and provides information on their native
interactions. The combination of BN-PAGEandSDS-PAGE tech-
niques (2D-BN-PAGE) has become the method of choice for
investigating the respiratory chain proteins in mitochondria
and other hydrophobic protein complexes. As shown in
Figure 3, only bands for the respiratory complexes I, II, III,
IV, and V could be visualized on the ﬁrst dimension of
2D-BN-PAGE. After SDS-PAGE, the subunits of each complex
were resolved (see Supplementary material online, Figure
S1). First, protein expression levels were compared and
found unchanged between the four groups (data not shown).
Next, protein phosphorylation was determined
by immunoblotting using a phosphorylation-speciﬁc anti-
phospho-Ser/Thr/Tyr antibody. With this approach, we
could detect 61 phosphorylated protein spots per gel
(Figure3). All spotswere subjected toMALDI-TOF-MSanalysis,
and 45 proteins were unequivocally identiﬁed and categor-
ized into the following ﬁve groups: (1) oxidative phosphoryl-
ation (21 subunits); (2) tricarboxylic acid cycle (eight
proteins); (3) fatty acid metabolism (11 subunits); (4) trans-
port (three proteins); and (5) chaperones (two proteins; see
Table 1 for details). Some proteins displayed multiple spots
generated by formation of different complexes, as observed
with oxoglutarate dehydrogenase (OGDH), ubiquinol–
cytochome c reductase complex core protein 2, aspartate
aminotransferase (AST), dihydrolipoyllysine-residue succinyl-
transferase (component of OGDH), aconitate hydratase,
malate dehydrogenase, short chain acetyl-CoA dehydrogen-
ase, and adenine nucleotide translocator-1 (ANT1). Interest-
ingly, six of the 61 protein spots were found to be ANT1
indicating that the abundant ANT1 protein forms various
complexes in the inner mitochondrial membrane. To better
compare the changes of phosphorylated protein spots, the
mitochondrial proteins from different groups were ﬁrst
resolved on a 4–13% BN-PAGE. Subsequently, each gel lane
was excised and cut into four parts, as indicated in Figure 3.
Matched parts were assembled on the top of a 12% SDS gel
and subjected to SDS-PAGE for the second dimension followed
by Western blotting with the anti-phospho-Ser/Thr/Tyr anti-
body. Phosphorylation of 11 spots from seven proteins were
found to be signiﬁcantly changed (Figure 4). Phosphorylation
Figure 2 Purity of mitochondrial preparations. Mitochondrial and cytoplasmic
fractions were immunoblotted with antibodies against adenine nucleotide
transporter (ANT), a marker of the inner mitochondrial membrane, voltage-
dependent anion channel 1 (VDAC1), a marker of the outer mitochondrial
membrane, NDUFS4 [NADH dehydrogenase (ubiquinone) Fe-S protein], and sar-
comeric mitochondrial creatine kinase (sMtCK); two other speciﬁc mitochon-
drial markers, calreticulin, a marker of the endoplasmic reticulum, catalase,
a marker of peroxisomes, and the cytosolic marker a-tubulin.
Figure 3 Separation of mitochondrial proteins by two-dimensional blue-
native/sodium dodecyl sulphate gel electrophoresis (2D-BN-PAGE) and detec-
tion of phosphoproteins. Mitochondrial preparations were ﬁrst resolved by 4–
13% BN-PAGE. Gel slides were cut into four parts, as indicated, and matched
parts were assembled on top of a 12% SDS gel for the second dimension
SDS-PAGE followed by Western blot with anti-phospho-Ser/Thr/Tyr antibody.
A total of 61 protein spots were found to be phosphorylated. Numbers refer
to the protein identiﬁcation presented in Table 1. Figure shows a representa-
tive 2D-BN-SDS gel of a control heart.
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Table 1 Phosphoprotein spots identiﬁed by matrix-assisted laser desorption/ionization-time of ﬂight mass spectrometry
Spot Protein name GI Mr (kDa) pI Score Reported phosphosites
Oxidative phosphorylation complex I
8 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75 kDa 53850628 80.331 5.65 667 T611 (human)
11 NADH dehydrogenase (ubiquinone) ﬂavoprotein 1 81883773 51.383 8.37 319
12 NADH dehydrogenase (ubiquinone) Fe-S protein 2 58865384 52.927 6.52 1052 Y141 (human)
14 NADH-ubiquinone oxidoreductase 39 kDa subunit 81882598 41.900 9.77 354
15 NADH-ubiquinone oxidoreductase 30 kDa subunit 23396786 (M) 30.360 6.40 85
16 NADH-ubiquinone oxidoreductase 24 kDa subunit 83305118 27.703 6.23 48
17 NADH dehydrogenase (ubiquinone) Fe-S protein 7 81883325 24.215 10.02 139
18 NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 6 94717662 (M) 15.374 9.79 87
19 NADH dehydrogenase 1 beta 4, fragment 82617686 9.813 9.74 156
20 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex subunit 6 32363398 (M) 15.273 10.10 285
Oxidative phosphorylation complex V
23 ATP synthase gamma subunit, mitochondrial precursor 21263432 (M) 32.979 9.06 330 Y77 (bovine), S146 (mouse)
24 ATP synthase B chain, mitochondrial precursor 114625 28.965 9.39 872
25 ATP synthase O subunit, mitochondrial precursor 20302061 23.440 10.03 603 Y35, Y46 (human)
26 ATP synthase, alpha subunit, mitochondrial precursor 83300587 55.218 8.28 118 S76 (mouse)
Oxidative phosphorylation, complex III
21, 27,32 ubiquinol–cytochrome c reductase complex core protein 2 122066611 48.400 9.16 548
28 cytochrome c-1 21759079 (M) 35.533 9.24 164
Oxidative phosphorylation, complex IV
40 cytochrome c oxidase subunit 3 117075 29.834 6.59 41
41 cytochrome c oxidase subunit 2 117043 26.130 4.60 280
42 cytochrome c oxidase subunit 4 isoform 1 117089 19.559 9.45 882
Oxidative phosphorylation, complex II
44 succinate dehydrogenase (ubiquinone) ﬂavoprotein subunit 52782765 72.596 6.75 493 Y535, Y596 (rat)
48 succinate dehydrogenase complex subunit B (fragment) 89573817 27.377 8.33 261
Tricarboxylic acid cycle
38 Fumarate hydratase, mitochondrial precursor 120605 54.714 9.06 508 Y491 (human)
52 Citrate synthase 81902084 52.176 8.53 1561 Y80 (human)
1, 5, 35, 39 2-Oxoglutarate dehydrogenase E1 component (alpha-ketoglutarate dehydrogenase) 81883712 117.419 6.30 218
2, 3 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate
dehydrogenase complex
62512126 49.236 8.89 228
4, 13, 22 Aspartate aminotransferase, mitochondrial precursor 112987 47.683 9.13 1544 Y96, Y401 (human)
36, 51 Aconitate hydratase, mitochondrial precursor 60391194 86.121 7.87 3476 Y71, Y544, Y655 (rat)
50 Isocitrate dehydrogenase (NADP), mitochondrial precursor 119364595 51.391 8.88 1868
55, 56 Malate dehydrogenase 81878914 (M) 36.089 8.92 527 Y56, Y80 (human)
Lipids metabolism
9 Propionyl-CoA carboxylase alpha chain 129684 78.289 6.33 268 S248 (mouse)
10 Propionyl-CoA carboxylase beta chain 129686 59.216 7.19 193
30 Trifunctional enzyme subunit alpha, mitochondrial precursor 2494234 83.202 9.11 266
31 Trifunctional enzyme subunit beta, mitochondrial precursor 2501192 51.667 9.50 934
43 Long-chain speciﬁc acyl-CoA dehydrogenase, mitochondrial precursor 113016 48.242 7.63 2248
45, 49 Acetyl-CoA dehydrogenase, short chain 81891723 45.224 8.47 851
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of cytochome c oxidase subunit 2 and OGDHwere increased in
groups subjected to ischaemia-reperfusion injury. In contrast,
phosphorylation of NDUFA9, AST, 2,4-dienoyl-CoA reductase,
prohibitin-2, and ANT1 were reduced in mitochondria from
unprotected hearts (Figure 4).
3.3. Identiﬁcation of novel phosphorylation sites
in cardiac mitochondrial proteins
We identiﬁed 26 different phosphorylation sites in 19 pro-
teins (Table 2). Twenty-four serine/threonine residues and
two tyrosine residues were found. Except for malate dehy-
drogenase, aconitate hydratase, and ANT1, the other 16
proteins could not be found by 2D-BN-PAGE/Western blot
with anti-phospho-Ser/Thr/Tyr antibody. Two of the 19 pro-
teins contained two distinct phosphorylation sites, while one
protein (pyruvate dehydrogenase E1 alpha subunit) con-
tained six different sites. The exact position of the phos-
phorylated residues could not be assigned in three
proteins. The MS/MS spectrum of ANT1, the major isoform
of the ADP/ATP translocator in the heart, containing a
phosphorylated tyrosine (Tyr194), is depicted in Figure 5.
Additional MS/MS spectra of identiﬁed phosphopeptides
are shown as online supplemental data (see Supplementary
material online, Figure S2).
3.4. Modulation of adenine nucleotide translocator
phosphorylation by pre and postconditioning
The phosphorylation of ANT1 is of particular interest, as this
protein is not only essential for the transport of ATP produced
by oxidative respiration, but is also thought to be an integral
component of the mitochondrial permeability transition
pore.6 To conﬁrm the changes in ANT phosphorylation by pre
and postconditioning, ANT protein was immunoprecipitated
from all samples, and the phosphorylation of ANTwas visual-
ized by Western blot with anti-phospho-Tyr antibody. As
shown in Figure 6, ANT phosphorylation was reduced after
ischaemia-reperfusion alone (unprotected state). ANTdepho-
sphorylation could be prevented by both protective thera-
pies, i.e. preconditioning and postconditioning.
3.5. Yeast model reveals pivotal role of Tyr194
of adenine nucleotide translocator-1 in
mitochondrial function
It is well-known that the ADP/ATP carriers (AACs), the yeast
homologues of themammalianANT,areessential for oxidative
phosphorylation, i.e. AAC-deﬁcient yeast grows exclusively
on fermentable media. Deletion of all the three AAC genes
in yeast results in oxidative phosphorylation-deﬁcient cells
unable to grow on respiratory carbon sources (JL-1-3 strain).
However, AAC-deﬁcient yeast can grow in the presence
of non-fermentable carbon sources, such as glycerol or
lactate if expressing any of the three human ANT isoforms.
Re-expression of human ANT1 restores growth of JL-1-3
yeast cells in both glycerol and lactate plates, as shown in
Figure 7. To test whether phosphorylation at Tyr194 is required
for yeast growth, we substituted Tyr194 by phenylalanine to
create a non-phosphorylatable residue in ANT1 (ANT1Y194F).
Re-expression of the ANT1Y194F mutant into JL-1-3 yeast
cells was unable to restore growth on non-fermentable
carbon sources (Figure 7). Hence, loss of ANT phosphorylation
at Tyr194 results in a defective oxidative growth phenotype.
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Similar results were obtained using a high expressing ANT1
vector (pRS424-hANT1; see Supplementary Material). Our
results provide evidence for a potential role of Tyr194 in
ANT1 in the context of cardioprotection.
4. Discussion
Our study focused on the systematic proﬁling of phosphopro-
teins in heart mitochondria. Since recent studies provide
evidence that reversible phosphorylation of mitochondrial
proteins is more common than previously expected,14–17
and that this might be essential in the context of cardiopro-
tection, we set out to assess the mitochondrial phosphopro-
teome in pre and postconditioned, i.e. protected heart
mitochondria, and to compare this with the mitochondrial
phosphoprotein proﬁle of unprotected hearts. The ultimate
goal was to identify novel anti-ischaemic targets. For this
purpose, a gel-based approach, combining 2D-BN-PAGE,23
Western blot analysis,24 and MALDI-TOF-MS, and a gel-free
phosphoproteomics approach including two phosphopeptide
enrichment steps followed by LC-ESI-MS/MS or LC-MALDI-MS/
MS25 were used. The native gel-based method is widely used
for both protein proﬁling and quantitative proteomic analyses,
speciﬁcally for organelles like mitochondria, but it may suffer
from difﬁculties in detecting low-abundance, very large, or
small proteins. Using this technique, we identiﬁed a total
of 61 phosphorylated proteins from rat heart mitochondria
covering a wide range of key mitochondrial functions such
as oxidative phosphorylation, tricarboxylic acid cycle, lipid
metabolism, and transport or chaperone activities. For
example, some oxidative phosphorylation units (NADH
dehydrogenase Fe-S protein 7, NADH dehydrogenase 1
beta-4, ubiquinol–cytochrome c reductase complex core
protein 2, cytochrome c oxidase subunit 4 isoform 1, and
succinate dehydrogenase complex subunit B), and many of
the proteins involved in lipid metabolism (propionyl-CoA
carboxylase beta chain, trifunctional enzyme subunit alpha
and beta, 2,4-dienoyl-CoA reductase, 3,2-trans-enoyl-CoA
isomerase, short chain 3-hydroxyacyl-CoA dehydrogenase,
and carnitine O-palmitoyltransferase 2) have not yet been
reported to be phosphorylated in cardiac mitochondria.
After selective enrichment of phosphopeptides and liquid
chromatography followed by mass spectrometry, we were
able to increase proteome coverage and to map 26 phos-
phorylation sites in 19 proteins. Many of the 26 identiﬁed
phosphorylation sites in cardiac mitochondrial proteins are
reported here for the ﬁrst time.26,27 Together, our obser-
vations suggest that phosphorylation may play a more promi-
nent regulatory role in heart mitochondria than previously
thought.
Although protective signalling pathways of pre and postcon-
ditioning converge at the mitochondrial level,5,7 little
is known about the post-translational modiﬁcations of
possible end-effectors involved in cardioprotection. Recently,
a number of protein kinases and phosphatases were found
to colocalizewith variousmitochondrial sub-compartments,9,11
but the ultimate targets of these kinases remain largely
unknown. Using an isolated rabbit heart model, Kim et al.28
compared the changes in protein expression of ischae-
mia-preconditioned mitochondria with non-preconditioned
mitochondria and identiﬁed 25 differentially expressed mito-
chondrial proteins. Most of these proteins were related to
Figure 4 Differentially altered phosphoprotein spots, as identiﬁed by comparative two-dimensional blue-native/sodium dodecyl sulphate gel electrophoresis
(2D-BN-PAGE) and Western blot analysis. Regions of 2D-blots with reproducible protein alterations were boxed, and the protein spots were identiﬁed by mass
spectrometry. NDUFA9, NADH dehydrogenase ubiquinone 1 alpha subcomplex 9; AST, aspartate aminotransferase; ANT1, adenine nucleotide translocator-1.
CTRL: time-matched perfusion; ISCH: hearts exposed to ischaemia-reperfusion; PreC, isoﬂurane preconditioning; PostC: isoﬂurane postconditioning. Data are
mean+ SD (n ¼ 4). Statistically signiﬁcant changes relative to CTRL are indicated using two-tailed unpaired t-test: *P , 0.05.
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Table 2 Phosphopeptides and phosphorylation sites identiﬁed by LC-MS/MS analysis
Protein name GI Peptide sequence Expect Ion
score
Observed
mass
Charge Phosphorylated
residue
Instrument
Malate dehydrogenase 122065494 AGAGSATLSMAYAGAR 3  1027 88 1535.68 2þ Ser-246b LTQ-FT
Malate dehydrogenase 122065494 AGAGSATLSMAYAGAR 2.6  1025 72 1534.67 1þ Ser-246b MALDI
ADP/ATP translocase 1 461475 AAYFGVYDTAK 0.0038 45 1286.56 2þ Tyr-194b LTQ-FT
ADP/ATP translocase 1 461475 AAYFGVYDTAK 0.00053 57 1285.54 1þ Tyr-194b MALDI
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YGMGTSVER 0.00065 48 1080.42 2þ Thr-231b LTQ-FT
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YGMGTSVER 7.5  1026 67 1080.42 2þ Ser-232 LTQ-FT
Pyruvate dehydrogenase E1 component, alpha subunit 548409 SMSDPGVSYR 0.0016 44 1179.46 2þ Ser-300 LTQ-FT
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YGMGTSVER 0.041 37 1079.43 1þ Ser-232 MALDI
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YGM*GTSVER 0.081 33 1095.41 1þ Ser-232 MALDI
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YGM*GTSVER 0.042 45 1095.41 1þ Tyr-227b MALDI
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YHGHSMSDPGVSYR 0.001 55 1753.64 3þ Ser-293 and Ser-300 LTQ-FT
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YHGHSMSDPGVSYR 1.7  1026 73 1673.66 2þ Ser-293 LTQ-FT
Pyruvate dehydrogenase E1 component, alpha subunit 548409 YHGHSMSDPGVSYR 0.023 42 1752.61 1þ Ser-293 and Ser-300 MALDI
Succinyl-CoA ligase (ADP-forming), beta-chain 52788305 INFDSNSAYR 0.00032 53 1267.52 2þ Ser-279 LTQ-FT
Succinyl-CoA ligase (ADP-forming), beta-chain 52788305 INFDSNSAYR 5.2  1026 76 1266.51 1þ Ser-279 MALDI
Ubiquinol-cytochrome c reductase complex 11 kDa
protein
62511137 ERLESCDRR 0.035 29 1300.54 1þ Ser-50b MALDI
Ubiquinol-cytochrome c reductase complex 11 kDa
protein
62511137 ERLESCDR 0.04 25 1144.47 1þ Ser-50b MALDI
NADH dehydrogenase (ubiquinone) ﬂavoprotein 3-like
isoform 1
162287192 DSSSSSSSSSSDSDSDGEEHGSDIGPRa 2  1028 100 2738.05 1þ NDb MALDI
Enoyl-CoA hydratase 119119 AVGKSLAM*EMVLTGDR 0.01 33 1773.84 1þ Thr-194b MALDI
Aconitate hydratase 60391194 WVVIGDENYGEGSSR 0.03 42 1747.7 1þ Ser-669b MALDI
Glycerol 3-phosphate acyltransferase, mitochondrial 8393466 WKESLMSR 0.012 35 1116.53 1þ Ser-57b MALDI
Glycerol 3-phosphate acyltransferase, mitochondrial 8393466 SDEEDEDSDFGEEQR 1.1  1025 71 1866.65 1þ Ser-695 MALDI
2-oxoisovalerate dehydrogenase subunit alpha,
mitochondrial precursor
129032 IGHHSTSDDSSAYR 1.2  1027 92 1612.6 1þ Ser-337 MALDI
2-oxoisovalerate dehydrogenase subunit alpha,
mitochondrial precursor
129032 SVDEVNYWDK 1.5  1025 72 1334.54 1þ Ser-343 MALDI
3-methyl-2-oxobutanoate dehydrogenase kinase 3183508 STSATDTHHVELARa 4.2  1029 108 1604.67 1þ Ser-31 or Thr-32b MALDI
TOM70 homologue A 47058988 ASPALGSGPDGSGDSLEM*SSLDR 2.2  1025 71 302.04 1þ Ser-94 MALDI
A kinase anchor protein 1, mitochondrial precursor 13959285 RRSESSGNLPSIVDTR 0.03 37 1853.9 1þ Ser-101 MALDI
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 6093508 NSTLSEEDYIER 71026 76 1535.65 1þ Ser-88 MALDI
Mitochondrial aspartate glutamate carrier 1 (solute
carrier family 25, member 12)
13124050 DVEVTKEEFAQSAIR 0.01 21 1801.88 1þ Ser-256b MALDI
heat shock 27 kDa protein 1 94400790 SPSWEPFR 0.0024 47 1085.4 1þ Ser-15 MALDI
similar to CG31759-PA 81884455 SPAEATTHEAVRa 0.04 38 1348.67 1þ Thr-26 or Thr-27b MALDI
hypothetical protein 123780395 DADEEDSDEETSHLER 1.6  1028 102 1956.79 1þ Ser-106b MALDI
regulator of microtubule dynamics 3 62078823 SQSLPNSLDYAQTSER 0.00015 63 1875.86 1þ Ser-46b MALDI
The phosphorylation sites are bold and oxidized methionines are denoted by the ‘*’ symbol. GI denotes GenInfo Identiﬁer (GenBank).
aThe exact position of the phosphorylated residue cannot be assigned. Phosphorylation sites were veriﬁed against either PhosphoSitePlus (http://www.phosphosite.org/homeAction.do) or Phospho.ELM (http://
phospho.elm.eu.org/index.html) databases, accessed February 25, 2008.
bNovel phosphorylation sites.
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respiratory chain and energy metabolism. In another study by
Arrell et al.,29 isolated rabbit cardiomyocytes were precondi-
tioned with adenosine and diazoxide, but no index ischaemia
was applied. After 2 h of drug exposure, whole cell lysates
were collected and subjected to 2D-gel electrophoresis. This
study identiﬁed 28 differentially expressed protein spots, the
majority ofwhich againwas involved in bioenergetics. Interest-
ingly, the same study also found four newphosphorylation sites,
one at theb-subunit of ATP-synthase.While both studies predo-
minantly focused on changes in protein expression, fundamen-
tal changes in heart physiology may typically occur without
changes in protein abundance but rather in response to post-
translationalmodiﬁcations such as phosphorylation. Comparing
thephosphorylation proﬁles of protected vs. unprotectedmito-
chondria, wewere able to identify seven proteins from 11 spots
that were differentially phosphorylated. Phosphorylation of
cytochrome c oxidase subunit 2 and OGDH were increased in
protectedandunprotectedmitochondria, suggesting thatphos-
phorylation of these proteins may be related to ischaemia-
reperfusion injury. In contrast, phosphorylation of NDUFA9,
AST, 2,4-dienoyl-CoA reductase, prohibitin-2, and ANT1 were
exclusively reduced by ischaemia-reperfusion alone, but
largely unaffected by both pre and postconditioning. Hence,
phosphorylation of these sites may be rather linked to
cardioprotection.
To test whether the observed phosphorylation of ANT1
was indeed linked to biological signiﬁcance and to exclude
the possibility of mere association or experimental arte-
facts, we determined the biological signiﬁcance of the
novel phosphorylation site of ANT1 at residue Tyr194. ANT,
called AAC in yeast, is the most abundant protein of the
inner mitochondrial membrane and belongs to the mito-
chondrial solute carrier family involved in a variety of trans-
port activities across the inner mitochondrial membrane.30
ANT facilitates the exchange of ADP/ATP by an antiport
mechanism and thus is essential for the utilization of ATP
produced by oxidative phosphorylation. Moreover, ANT is
thought to be an integral component of the mitochondrial
permeability transition pore (mPTP),19 albeit this function
is still under debate.31 Current evidence suggests that
cardioprotection by pre and postconditioning is ultimately
mediated through the inhibition of mitochondrial per-
meability transition. Baines et al.32 reported that PKC1
closely interacts with cardiac mitochondria implying that
components of the mPTP complex might be the principal
target of this kinase. In our study, we could show that
ischaemia-induced ANT dephosphorylation could be pre-
vented or reversed by both pre and postconditioning. A
major phosphorylation site of ANT was identiﬁed on Tyr194,
which is the last of three tyrosines Tyr186/Tyr190/Tyr194
forming a ladder along the transmembrane helix H4 oriented
towards the cavity of the channel.30,33 A ‘stacking inter-
action’ with the tyrosine rings could guide the nucleotides
along this tyrosine ladder, and phosphorylation of Tyr194
could markedly interfere with or modulate the process.
Intriguingly, in yeast we could show that mutation of Tyr194
to Phe, mimicking the non-phosphorylated state, failed to
rescue cellular growth on a non-fermentable carbon source
when transforming the human ANT1 into the AAC-deﬁcient
yeast strain JL-1-3. Therefore, our results provide evidence
that this phosphorylation site is critical for mitochondrial
bioenergetics, which is in accordance with the previous
reports showing that tyrosine phosphorylation of
Figure 5 MS/MS spectrum of the tyrosine phosphopeptide (Y194) of adenine
nucleotide translocator-1 (ANT1). Precursor ion mass and MS/MS were
measured in LTQ-FT mass-spectrometer. Arrows indicate phosphate loss in
the indicated ions. The measured masses of b- and y-ions are in italic.
Figure 6 Phosphorylation of adenine nucleotide translocator (ANT) in heart
mitochondria. ANT protein was immunoprecipitated from 50 mg of puriﬁed
rat heart mitochondrial fractions and subjected to Western blot with
anti-phospho-tyrosine antibody. Representative Western blots (upper) and
averaged density data of phosphorylated tyrosine of ANT (p-Tyr) compared
with total ANT (t-ANT) are shown for each group. IgG LC: light chain of
goat ANT antibody; CTRL: time-matched perfusion; ISCH: hearts exposed to
ischaemia-reperfusion alone; PreC, isoﬂurane preconditioning; PostC: isoﬂur-
ane postconditioning. Data are mean+ SD (n ¼ 4). *P , 0.05 vs. ISCH.
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mitochondrial proteins is enhancing ATP production.34
Although the yeast experiments extend our proteomic ﬁnd-
ings from isolated rat hearts showing that Tyr194 phos-
phorylation of ANT1 is associated with cardioprotection,
future experiments using hypoxia/reoxygenation will have
to prove this concept in mammalian cells.
In our comparative phosphoproteomics study, we used
2D-BN-PAGE-coupled Western blotting with an antibody
speciﬁc for phospho-Ser/Thr/Tyr. Although this approach is
comparable with those using ﬂuorescent phosphosensor
dyes (ProQ Diamond dye), it is conceivable that some phos-
phoproteins may remain undetected by either methods.35 In
addition, some proteins may be dephosphorylated during
the mitochondria isolation process or even during BN-PAGE.
Because of the lack of antibodies, we were unable to
conﬁrm all the observed changes in phosphorylation by immu-
noprecipitation. Besides phosphorylation, we found other
modiﬁcations inmitochondrial proteins. For example, trypto-
phan modiﬁcations (kynurenine and formylkynurenine),
which have a profound impact on cell death and survival and
are implicated in a number of pathologies,36 were frequently
observed in our study (data not shown). This is not so much
surprising since mitochondrial proteins are exposed to high
amounts of reactive oxygen species. In addition, histidine37
and cysteine38 phosphorylation was also observed (His292 of
pyruvate dehydrogenase E1 alpha subunit and Cys63 of sarco-
meric mitochondrial creatine kinase). Although histidine and
cysteine phosphorylation were previously reported, their
physiological relevance remains largely unknown. In the
current study, the halogenated ether isoﬂurane was used to
elicit pre and postconditioning in hearts. This class of drugs
was proven to be of value in the clinical setting of patients
undergoing coronary artery bypass grafting surgery.39,40
However, it is possible that other pre and postconditioning
mimicking agentsmay elicit different phosphoprotein proﬁles
in heart mitochondria.
In summary, our comparative analysis of mitochondrial
phosphoproteins in pre and postconditioned, i.e. protected
vs. unprotected mitochondria, revealed a total of 61 phos-
phoproteins including 26 phosphorylation sites and it
proved to be an effective approach for elucidating the mol-
ecular events underlying ischaemic injury and protective
mechanisms. A major phosphorylation site was identiﬁed
in ANT1 at Tyr194. The substitution of this site with Phe,
mimicking the non-phosphorylated state, resulted in the
complete inhibition of oxidative growth in the yeast model
suggesting that phosphorylation at this novel site is critical
for bioenergetics and may thus substantially contribute to
cardioprotection.
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Research online.
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